|
Physician.com promises to be the #1 destination for high tech physicians and discerning patients on the Internet today.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
From the Staff at Physician.com
|
|
|
Physician.com is now offering a "Money for Doctors" section on our website to help doctors find funding for their offices and services. We understand how difficult it can be to maintain a state of the art office for your patients and the high expense of purchasing new equipment that will help your patients live a more rewarding life.
Let Physician.com help you with funding your office and sleep better at night knowing that we can help you with your needs today.
|
|
Army Personnel Show Increased Risk For Migraine - Condition Underdiagnosed, Mistreated
Two new studies show that migraine headaches are very common among U.S. military personnel, yet the condition is frequently underdiagnosed. The studies, appearing in Headache, the peer-reviewed journal of the American Headache Society, examine the incidence among soldiers within 10 days of returning from a 1-year combat tour in Iraq , as well as U.S. Army officer trainees. The U.S.
Lyme-Like Illness To Be Studied In Texas
Tao Lin, D.V.M., and Steven J. Norris, Ph.D., both with the Department of Pathology and Laboratory Medicine at The University of Texas Medical School at Houston, have been named grant recipients of the Norman Hackerman Advanced Research Program (ARP) by the Texas Higher Education Coordinating Board.
FDA Approves First Generic Divalproex Sodium To Treat Seizures, Migraine Headaches And Bipolar Disorder
The U.S. Food and Drug Administration approved the first generic versions of Depakote delayed-release tablets (divalproex sodium). Depakote is approved by the FDA for the treatment of seizures, bipolar disorder and migraine headaches. "Generic drugs undergo a rigorous scientific review to ensure that they will provide the patient with the same amount of high quality, safe and effective drug as the name brand product," said Gary J.
Gene May Put Women With Migraine At Increased Risk Of Heart Disease And Stroke
Women who experience migraine with aura appear to be at an increased risk of heart disease and stroke if they have a certain gene, according to a study published in the July 30, 2008, online issue of Neurology®, the medical journal of the American Academy of Neurology. For the study, researchers followed 25,001 Caucasian women for the occurrence of cardiovascular disease, including heart attacks and ischemic stroke.
UPMC Conference To Discuss Newest Scientific Knowledge Forcing Doctors To Re-Think How To Safely Manage Concussions In Athletes Of All Levels
Treatment of concussions remains arguably the most complex and controversial issue in sports medicine for athletes of all ages, yet concussions occur in millions of athletes each year. The good news is that new scientific research continues to provide clearer knowledge for team doctors and athletic trainers, helping them to recognize and quantify the symptoms and effects of concussions.
News Tips From The Journal Of Neuroscience
1. Hodgkin CHuxley Model of Backpropagating Spikes Yuguo Yu, Yousheng Shu, and David A. McCormick Axon potentials recorded in somata of pyramidal neurons in vivo have a fast rising phase and variable threshold, contrary to predictions of the Hodgkin¨CHuxley model. Some have suggested that this difference is due to cooperativity among sodium channels, resulting in many channels opening simultaneously. Yu et al.
Oxygen Therapy Might Ease Pain Of Migraine, Cluster Headaches
Two types of oxygen therapy could offer some relief to adults who suffer from disabling migraine and cluster headaches, according to a new research review from Australia. Migraine headaches are severely painful and usually occur with other symptoms such as nausea, vomiting and painful sensitivity to light. Cluster headaches cause sharp, burning pain on one side of the head.
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial In Patients With Migraine
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced it has initiated its Phase 3 clinical program to evaluate MAP0004 as a potential treatment for migraine. MAP0004 is orally inhaled and self-administered at home using MAP Pharmaceuticals' proprietary Tempo(R) inhaler. In the company's prior Phase 2 efficacy study, MAP0004 provided pain relief in as fast as 10 minutes, with relief sustained through at least 24 hours.
FDA Panel Rejects Black Box Warning On Epilepsy Drugs
A panel of experts that advises the US Food and Drug Administration (FDA) voted last week to reject the Agency's proposal to make manufacturers of 11 epilepsy drugs put the strongest level of warning label on their products (the Black Box warning). The FDA had recommended the Black Box warning because studies showed the drugs had nearly double the risk of suicide compared to placebo, although in absolute terms it was still quite small.
Men And Women With History Of Concussion Mend Differently, Study Finds - Concussion Treatment Needs To Be More Individualized
Female soccer players and soccer players who have had a previous concussion recuperate differently from males or players without a history of concussion, new research released at the 2008 American Orthopaedic Society for Sports Medicine Annual Meeting at JW Marriott Orland Grande Lakes shows. The study found that prior history of concussion and gender account for significant differences in test results following the injury.
Combination Drug Taken Early Relieves Migraine Symptoms
A combination drug taken within an hour after the start of a migraine is effective in relieving symptoms, according to research published in the July 8, 2008, issue of Neurology®, the medical journal of the American Academy of Neurology.
NuPathe Reports Positive Phase I Results For NP101, A Novel Transdermal Patch For Acute Migraine
NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, announced positive Phase I results for NP101, a novel drug-device patch for acute migraine in clinical development.
Canadian Scientists Report On Pain Research At NIDCR's 60th Anniversary Symposium
Nearly everyone has experienced the acute, short-lived pain that occurs after a mild injury, but recent surveys reveal that more than 20% of the population has a chronic pain condition (i.e., pain that has lasted for 3 months or more) and for which treatment is often not very effective (e.g., low back pain, fibromyalgia, migraine headaches). Acute and chronic pain conditions have huge socio-economic costs.
Migraine Mutations Reveal Clues To Biological Basis Of Disorder
Fifteen percent to 20 percent of people worldwide suffer from migraines excruciating headaches often presaged by dramatic sensations, or "auras." By studying a rare, inherited form of migraine, researchers at Vanderbilt University Medical Center have found clues to the biological basis of the painful, debilitating disorder. In the Proceedings of the National Academy of Sciences, Alfred George Jr., M.D.
Zogenix Announces Clinical Study Results For Sumatriptan DosePro™, A Novel Migraine Treatment
Zogenix, Inc. ("Zogenix"), a private, specialty pharmaceutical company, announced that it will present successful results from two clinical studies of sumatriptan DosePro, a product in development for treatment of acute migraine and cluster headache, at the 50th Annual American Headache Society Meeting in Boston, Massachusetts.
Merck's Investigational Migraine Treatment Telcagepant Improved Pain And Migraine-Associated Symptoms In Phase III Study
Merck & Co., Inc. announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of migraine pain and migraine-associated symptoms two hours after dosing compared to placebo.
Data On Highly Effective Migraine Treatment Presented By OptiNose
OptiNose has announced that it presented important new data demonstrating the superior performance of its novel nasal drug delivery device with sumatriptan for the treatment of migraines. The Phase II results indicate that the drug-device combination achieves migraine relief as quickly and efficiently as injections without the discomfort, inconvenience and risk of needle-stick injuries. OptiNose presented the data at the Annual Scientific Meeting of the American Headache Society in Boston.
MAP Pharmaceuticals Reports Positive Pharmacological Response Data For Migraine Product Candidate At The American Headache Society Annual Meeting
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) presented data from an in-vitro study evaluating receptor pharmacology of MAP0004, orally inhaled dihydroergotamine (DHE) for the potential treatment of migraine, compared to intravenous (IV) DHE. The study results were among six posters relating to the MAP0004 program that the Company presented at the American Headache Society 50th Annual Scientific Meeting in Boston, MA.
Migraine "Gun" Zaps Pain With The Touch Of Button - FDA Close To Approving Device That Uses Magnetic Bursts To Stop Pain
There are some 30 million Americans who suffer from migraine headaches.* Researchers at Ohio State University Medical Center have unveiled a new device that can control the pain of migraine headaches with no drugs, no injections, and no side effects. In fact this device is as easy as touching a button. After nearly eight years of development the migraine zapper could be on the market in a matter of months.
Knowledge And Understanding Ease Headache Frustrations
Headache frustrations are set to ease, thanks to a new range of patient leaflets. Produced by Lifting The Burden, the World Health Organization's Global Campaign to Reduce the Burden of Headache Worldwide, they will help sufferers understand and manage their headache more effectively. Almost all of us will have had a headache, but for many people it is more than just an irritant.
Medtronic Announces First Clinical Data On Occipital Nerve Stimulation For Chronic Migraine
Medtronic, Inc. (NYSE: MDT) announced that data from a multicenter, prospective, randomized, singleblinded, Controlled investigational study using its neurostimulation system to stimulate the occipital nerves as a potential approach to treating medically refractory chronic migraines will be presented during a late-breaking session at the annual scientific meeting of the American Headache Society (AHS) tomorrow in Boston.
Portable Device Effective In Zapping Away Migraine Pain
A novel electronic device designed to "zap" away migraine pain before it starts has proven to be the next form of relief for those suffering from the debilitating disease, according to a study conducted at The Ohio State University Medical Center. Results of the study, presented TODAY (6/27) at the annual American Headache Society meeting in Boston, found that the experimental device is safe and effective in eliminating headaches when administered during the onset of the migraine.
Headache Specialists Convene In Boston For 50th Annual American Headache Society Meeting
Headache specialists meet in Boston for the 50th annual meeting of the American Headache Society. Learn more about headache and face pain developments of the last 50 years -- including the top five advances in headaches -- and what researchers envision for the future.
Alexza Pharmaceuticals To Present AZ-104 Phase 2a Clinical Data At The American Headache Society Annual Scientific Meeting
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American Headache Society, which being held at the Marriott Boston Copley Place in Boston, MA.
Treating Chronic Pain, Migraine & Muscle Spasticity Through Inhibition Of Neurotransmitter Glutamate
A Webinar hosted by TorreyPines Therapeutics, Inc. (NASDAQ: TPTX) at 11 a.m. EDT on June 25 will bring together industry experts to discuss the opportunity of treating chronic pain, migraine and muscle spasticity through the inhibition of the neurotransmitter glutamate. The company's President and Chief Executive Officer, Neil Kurtz, M.D., will moderate a discussion following brief presentations by: Tony Yaksh, Ph.D.
|
|
|
 |
|
WHO Proposes Strategy For Prevention And Control Of Cancer In The African Region
The World Health Organization (WHO) has proposed a strategy to prevent and control cancer, 582 000 cases of which were recorded in the Region in 2002. Cancer of the cervix, breast, liver and prostate as well as Kaposi's sarcoma and non-Hodgkin's lymphoma are the most common forms of cancer in the African Region. Incidence of these cancers are projected to double by 2020 if effective interventions are not intensified.
Cellvizio(R) Imaging System Improves Bile Duct Cancer Detection According To A New Study In Clinical Gastroenterology And Hepatology
A new imaging system that allows physicians to examine tissue at the cellular level from inside the body may now enable them to more effectively diagnose cancer of the bile ducts, according to a new study in the September 2008 issue of the journal Clinical Gastroenterology and Hepatology. This cancer, medically known as cholangiocarcinoma, is one of the most difficult to detect and treat.
New Reporting From IntrinsiQ Measures Impact Of Key Events On Oncology Drug Usage
IntrinsiQ, LLC, the expert source for clinical oncology insight, launched Event IntelliView, a new analysis tool that quantifies the real-world impact of key events in the lifecycle of medical oncology drugs. Pharmaceutical research teams can now quickly make sense of vast amounts of product performance data, and see how activities like reporting on clinical findings, regulatory approvals and price changes positively or negatively impact market penetration.
Clinical Trial Protocol Against Cancer Therapy Side Effects (Mucositis) Approved
Anadis Ltd. (ASX:ANX; OTC:ANDIY) an Australian biopharmaceutical company specializing in oral immunotherapy using naturally derived antibodies and other proteins is announcing the clinical protocol for its Cancer-related Mucositis Program was cleared by the Tel Aviv Souraski Medical Center's Institutional Review Board (IRB) and by the Israeli Ministry of Health (MOH). This enables the initiation of the clinical trial addressing this significant target at the medical center within a month.
Height Linked To Risk Of Prostate Cancer Development And Progression
A man's height is a modest marker for risk of prostate cancer development, but is more strongly linked to progression of the cancer, say British researchers who conducted their own study on the connection and also reviewed 58 published studies. In the September issue of
Human Genome Sciences Reports Initial Results Of Randomized Phase 2 Trial Of HGS-ETR1 In Combination With Bortezomib In Advanced Multiple Myeloma
Human Genome Sciences, Inc. (Nasdaq: HGSI) reported initial topline results from an ongoing randomized Phase 2 clinical trial of its TRAIL receptor antibody HGS-ETR1 (mapatumumab) in combination with bortezomib (Velcade) in patients with advanced multiple myeloma. The initial data from the multiple myeloma study show that HGS-ETR1 was well tolerated and suggest that disease response was comparable for this combination vs. bortezomib alone.
Link Between Nationality And Cervical Cancer
Gynaecological screening tests for cervical cancer have been available to all women in Sweden for almost four decades. Despite this, many immigrant women have a higher risk of developing the disease than Swedish-born women, according to a new study from the Swedish medical university Karolinska Institutet.
IU Simon Cancer Center's Tissue Bank Collecting Samples Sept. 20 At Clarian North
Would you like to contribute to breast cancer research? You can help by donating a tissue sample to the Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center from 9 a.m. to 2 p.m. Saturday, Sept. 20, at Ology Spa at the Clarian North Medical Center, 11700 North Meridian St., Carmel. A tissue sample will be taken from one breast with a needle and local anesthesia. The amount of tissue taken is about one gram (or the size of two peas).
Brain Cancer Patients Treated Using Fast And Efficient RapidArc Radiotherapy Technology From Varian Medical Systems
Two leading cancer centers have carried out groundbreaking radiosurgery treatments for multiple brain metastases using new RapidArc radiotherapy technology from Varian Medical Systems (NYSE:VAR). The MIMA Cancer Center in Melbourne, Florida and VU University Medical Center in Amsterdam, Netherlands were each able to treat brain metastases more quickly and efficiently than would have previously been possible.
Moffitt Cancer Center Receives Prestigious SPORE Grant Worth More Than $10 Million
The National Cancer Institute (NCI) has awarded Dr. Gerold Bepler , program leader for thoracic oncology at
Rates Of Oesophageal Cancer In UK Among The Worst In Europe
Call for national research study to investigate the causes of oesophageal cancer The Barrett's Oesophagus Foundation would like to support the Chief Medical Officer's recommendation for a large scale national research study to investigate the risk factors associated with the rising rate of cancer of the oesophagus. This was included in his Annual Report published yesterday, which raised grave concern over the sharp rise in oesophageal (gullet) cancer over the last two decades.
How Research Is Tackling Cancer: Free Public Lecture In Newcastle
Cancer touches many people, but few have the chance to meet the researchers who have dedicated their lives to tackling the disease. This month two world renowned cancer researchers will give a free public lecture in Newcastle to explain how their research is contributing to a better understanding of cancer and more effective treatments.
'Tanorexia' Common Among University Students According To Survey
A new study conducted at a large university finds more than 25 percent of those surveyed reported symptoms of tanning dependence, including symptoms similar to alcohol and drug-addicted individuals. Suggestively, the study also found those with a tanning dependence tend to be more likely to be thin and smoke cigarettes than others. The study by researchers at Fox Chase Cancer Center is published in the September/October issue of the American Journal of Health Behavior.
Ezetimibe And Cancer Link Still Not Clear Say Experts
The link between cholesterol-lowering drug ezetimibe (marketed as Vytorin) and cancer is still not clear, wrote the editors of the leading medical journal New England Journal of Medicine (NEJM). More time is needed to assess the drug, they said, and in the meantime patients and doctors will have to live with the uncertainty.
ProsCan For Men: Randomised Controlled Trial Of A Decision Support Intervention For Men With Localised Prostate Cancer
UroToday.com - With advances in treatment for prostate cancer and the often deleterious side-effects of treatment, newly diagnosed men are faced with difficult treatment decisions. For men with localised disease, the complexity of treatment decision-making is enhanced by the notion that some tumours are indolent in nature and therefore unlikely to ever cause clinical concern or death if left untreated.
Potential To Prevent Recurrence Of Bladder Tumors After Surgical Removal Of Upper Urinary Tract Transitional Cell Carcinoma
UroToday.com - In this article from the International Journal of Urology, the authors evaluated the survival benefit and prevention of bladder cancer recurrence with adjuvant platinum based chemotherapy, in upper urinary tract urothelial cancer, following surgical resection. Between April 1986 and August 2005, 132 patients with upper urinary tract urothelial cancer underwent radical nephroureterectomy with bladder cuff.
U.S. Phase 2 Combination Clinical Trial For Non-Small Cell Lung Cancer Patients With K-RAS Or EGFR-Activated Tumours
Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours. The Principal Investigator is Dr.
Debiopharm And EPFL Sign Research Project Agreement To Identify Inhibitors Of Signalling Pathways Controlling Cell Fate For Cancer Treatment
Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, announced the signature of a research project with the Ecole Polytechnique Federale de Lausanne (EPFL), aimed at the identification of novel small molecules and peptides that interfere with pathways controlling cell fate specification.
New Discovery About Growth Factor Can Be Breakthrough For Cancer Research
A research team at the Ludwig Institute and Uppsala University has discovered an entirely new signal path for a growth factor that is of crucial importance for the survival and growth of cancer cells. This discovery, published in today's issue of Nature Cell Biology, opens up an entirely new landscape for research on breast and prostate cancer, among other types. Our cells' ability to understand signals from various growth factors is critical for normal fetal development.
World Cancer Declaration Sets Ambitious Targets For 2020
A summit of more than 60 high-level policymakers, leaders and health experts have adopted a global plan aimed at tackling the growing cancer crisis in developing countries. The plan, contained in the World Cancer Declaration, recommends a set of 11 cancer-busting targets for 2020 and outlines priority steps that need to be taken in order to meet them.
New Approach To Treating Endometrial Cancer Discovered By TGen And Washington University Researchers
Researchers at the Translational Genomics Research Institute (TGen) has announced a new approach to treating endometrial cancer patients that not only stops the growth of tumors, but kills the cancer cells. In a potentially major breakthrough, TGen scientists and collaborators at Washington University School of Medicine in St.
Landmark Study Opens Door To New Cancer, Aging Treatments
Researchers at The Wistar Institute have deciphered the structure of the active region of telomerase, an enzyme that plays a major role in the development of nearly all human cancers. The landmark achievement opens the door to the creation of new, broadly effective cancer drugs, as well as anti-aging therapies. Researchers have attempted for more than a decade to find drugs that shut down telomerase widely considered the No.
REVLIMID(R) Demonstrates Activity Against Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
Celgene International SÃ rl (Nasdaq:CELG) announced the publication of peer-reviewed data from a Phase II study of REVLIMID in relapsed or refractory aggressive non-Hodgkin's lymphoma in the Journal of Clinical Oncology. According to the data, REVLIMID, as an oral monotherapy, demonstrated activity in patients at an advanced stage of the disease who had received a median of four prior treatments and had limited treatment options.
Study Reveals Genetic Links To Common Form Of Leukaemia
For the first time researchers have proved that there is a genetic susceptibility to developing chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in the Western world. Whilst anecdotal evidence has suggested that inherited factors play a role in the development of CLL, scientists have until now been unable to prove a genetic basis.
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
ImClone Systems Incorporated (NASDAQ: IMCL) announced overall survival results from BMS CA225-099 (BMS-099), an open-label Phase 3 study of ERBITUX® (cetuximab) in combination with a taxane and carboplatin in the first-line treatment of all histological subtypes of advanced non-small cell lung cancer (NSCLC).
|
|
|
|
Battling Diabetes With Beta Cells
Affecting eight percent of America's population, diabetes can lead to blindness, kidney failure, strokes and heart disease. Thanks to Tel Aviv University researchers, a new cure - based on advances in cell therapy - may be within reach. Prof. Shimon Efrat from TAU's Sackler Faculty of Medicine, whose research group is among world leaders in beta cell expansion, has developed a way to cultivate cells derived from insulin-producing beta cells from human tissue in the laboratory.
How Gastric Bypass Rapidly Reverses Diabetes Symptoms
A report in the September Cell Metabolism, a publication of Cell Press, offers new evidence to explain why those who undergo gastric bypass surgery often show greater control of their diabetes symptoms within days. It also helps to explain why lap-band surgery doesn't offer the same instant gratification. By studying mice that have undergone both procedures, the researchers show that changes in the intestine are the key.
Are Diabetes And Obesity Linked To Periodontitis?
The University of Illinois at Chicago has received a two-year federal grant to continue a study on how periodontitis, an inflammatory disease of the tissues surrounding teeth, is linked to type 2 diabetes and obesity. Dr. Keiko Watanabe of the UIC College of Dentistry has found that periodontitis accelerates the onset of insulin resistance in rats fed a high-fat diet.
Triumphs And Tragedies In Advances In The Management Of Patients With Diabetes Mellitus:
The need for long term studies to establish the best means of treating Diabetes, was underlined by Prof John Cleland from the University of Hull at the ESC Congress in Munich. Prof Cleland listed the latest treatment available for patients and voiced his concern about the side-effects and efficacy of available anti-diabetic drugs.
New Stories Of Diabetes In Pregnancy
Diabetes UK has enhanced and extended the Pregnancy and diabetes section of its website. These webpages help to explain the diverse issues that affect women with diabetes when planning for a family and during their pregnancy. The site provides information to support expectant parents, their families and healthcare professionals.
Come To Diabetes UK Roadshow In Leicester
Come down and visit the Diabetes UK roadshow in Leicester on Sunday 14 September. The huge pink lorry will be in the town centre from 11am to 6pm and anyone is welcome to drop in. Free diabetes screening will be available at the roadshow throughout the day. Diabetes UK staff, including a Care Advisor and local healthcare professionals will be available throughout the day to provide information and support to anyone affected by diabetes.
Advances In The Management Of Patients With Diabetes Mellitus
Disappointing results of latest treatments of blood glucose which have not convincingly reduced problems, apart from sub-clinical micro-vascular disease Current drugs offer little evidence that treatment of moderate hyperglycaemia is of benefit to patients.
Emerging Diabetes Drugs Consider Beta Cell Mass And Function As An Important Target
The next generation of diabetes drugs still is focused on metabolic approaches, but activities to preserve or even regenerate pancreatic islet cell mass and function are gaining momentum The Business Intelligence firm La Merie S.L. reported from its most recent analysis of emerging diabetes drugs and targets that of the 59 different treatment modalities in clinical development, the majority (36) were metabolic approaches.
DES In Diabetic Patients
The issue of using or not using DES in patients with diabetes will be debated between Professor Wijns, who discourages DES and Professor Silber, who feels that they should be used. Diabetes is increasingly viewed as a coronary artery disease equivalent.
SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI
Patients with both diabetes and advanced blockages in at least three heart vessels will find good news in new findings announced from the CARDia trial, says The Society for Cardiovascular Angiography and Interventions (SCAI). The one-year findings of the new study indicate that these patients can safely choose to undergo angioplasty and stenting rather than open-heart surgery.
Diamyd Medical: Diamyd Medical's NTDDS Technology Effective Against Diabetes Pain
Diamyd Medical (Pink Sheets:DMYDY)(STO:DIAMB) reports that its Nerve Targeting Drug Delivery System (NTDDS) expressing enkephalin, is effective in preclinical models of diabetes pain. Dr. David Fink, published in the scientific journal "Journal of Neuroscience" that Diamyd Medical's proprietary NTDDS platform, expressing enkephalin, effectively relieves pain due to diabetes in animals.
Newer Blood Pressure Drug Shows Promise As Alternative To ACE Inhibitors For Some Patients
Researchers in Canada working on an international study, discovered that the angiotensin-receptor blocker (ARB) telmisartan, a newer type of drug for lowering blood pressure, showed a modest reduction in cardiovascular deaths, strokes and heart attacks in patients with heart problems and diabetes who can't tolerate the standard and more widely used angiotensin-converting-enzyme (ACE) inhibitors.
British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines
With some 20,000 UK children with Type 1 diabetes(i) about to start the new school year, new guidance from the National Institute for Health and Clinical Excellence (NICE) looks set to revolutionise the way children manage their diabetes, granting more freedom and control for their condition, by greater access to insulin pump therapy.
CIRM Applauds The Reprogramming Of Pancreas Cells To Produce Insulin
The California Institute for Regenerative Medicine (CIRM), the state stem cell agency, issued the following statement regarding the research published in Nature by a team from Harvard that showed it is possible to take a type of adult pancreas cell that doesn't normally produce insulin and reprogram them to produce insulin. CIRM applauds the creativity and value in the research reported and shares the excitement in the promise it might hold.
Preventing Type 2 Diabetes - Can You Help? UK
Diabetes UK is organising a ground breaking event bringing together national and international academics as well as policy makers to discuss and decide future research priorities into the prevention of Type 2 diabetes. We need people with diabetes and at risk of diabetes to bring their expertise of living with Type 2 diabetes.
Telmisartan Modestly Reduces Major Cardiovascular Events In Patients Unable To Tolerate Ace Inhibitors (Transcend Study)
The angiotensin-receptor blocker (ARB) telmisartan should be regarded as a potential treatment for vascular disease or high-risk diabetes, in the 20% of patients who are unable to tolerate the standard treatment of angiotensin-converting enzyme (ACE) inhibitors.
Nearly Nine Out Of Ten Patients With Type 2 Diabetes Achieve QoF HbA1c Targets With Repaglinide And Metformin
Nearly nine out of ten patients with type 2 diabetes achieved the Quality Outcomes Framework (QoF) HbA1c target of
Amylin Pharmaceuticals And Eli Lilly Provide Context For FDA Alert For BYETTA
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) in a conference call today provided context and additional information regarding the August 18, 2008 U.S. Food and Drug Administration (FDA) update to a prior alert for BYETTA(R) (exenatide) injection referencing pancreatitis. The companies were aware of the pancreatitis cases referenced in the alert, as well as others, and previously reported these cases to the FDA.
CYPHER Sirolimus-eluting Coronary Stent Outperforms The Taxus® Stent In People With Diabetes
In patients with diabetes, the CYPHER® Sirolimus-eluting Coronary Stent outperformed the Taxus® Stent with significantly lower rates of in-segment restenosis (a reblockage within the stented area), target lesion revascularization (TLR; the need for another interventional procedure) and major adverse events (MACE, a composite of death, heart attack and TLR) at nine months according to clinical data appearing recently in the Journal of the American College of Cardiology.
Why Transplanted Insulin Cells Die
New research can enhance survival of islets transplants and improve treatment of type 1 diabetes. Transplantation of insulin-producing cell islets, so-called islets of langerhans is an appealing strategy for treatment of type 1 diabetes. But it turns out that these are short-lived, and the procedure needs to be repeated.
The CYPHER® Sirolimus-eluting Coronary Stent Outperforms The Taxus® Stent In People With Diabetes
In patients with diabetes, the CYPHER® Sirolimus-eluting Coronary Stent outperformed the Taxus® Stent with significantly lower rates of in-segment restenosis (a reblockage within the stented area), target lesion revascularization (TLR; the need for another interventional procedure) and major adverse events (MACE, a composite of death, heart attack and TLR) at nine months according to clinical data appearing recently in the Journal of the American College of Cardiology.
Drug Improves Kidney Function In Diabetics Pentoxifylline Prevents Protein Leakage Into Urine
Pentoxifylline, a drug used to treat patients with circulation problems, may also benefit those with kidney disease caused by diabetes and other conditions. Specifically, pentoxifylline decreases proteinuria, the abnormal leakage of protein into the urine, according to two articles in the September issue of the American Journal of Kidney Diseases, the official journal of the National Kidney Foundation.
Hitting A Home Run With Diabetes: College Coach And Catcher Team Up On And Off The Field
RBIs, batting averages, home runs, ERAs, strikeouts -- there are many numbers to keep track of in baseball. Some players and coaches have to watch other numbers, too, like blood glucose levels, carbohydrates, and insulin units.
American Diabetes Wholesale Announces 2008 Diabetes Educator Of The Year Contest
American Diabetes Wholesale, a discount provider of diabetic supplies to individuals without insurance, announced their 2nd annual Diabetes Educator of the Year Award contest recently at the American Association of Diabetes Educators 2008 International Diabetes Educators Conference in Washington, D.C.
Class Of Diabetes Drugs Carries Significant Cardiovascular Risks
A class of oral drugs used to treat type 2 diabetes may make heart failure worse, according to an editorial published online in Heart Wednesday by two Wake Forest University School of Medicine faculty members. "We strongly recommend restrictions in the use of thiazolidinediones (the class of drugs) and question the rationale for leaving rosiglitazone on the market," write Sonal Singh, M.D., M.P.H., assistant professor of internal medicine, and Curt D. Furberg, M.D., Ph.D.
|
|
|
|
|